Genetically predicted levels of the human plasma proteome and risk of stroke: a Mendelian Randomization study

Lingyan Chen¹⁺, James E. Peters², Bram Prins¹, Elodie Persyn^{1,3}, Matthew Traylor⁴⁺, Praveen Surendran^{1,5}, Savita Karthikeyan¹, Ekaterina Yonova-Doing¹⁺, Emanuele Di Angelantonio^{1,6,7,8}, David J. Roberts^{7,9,10}, Nicholas A. Watkins¹¹, Willem H. Ouwehand^{6,11,12,13}, John Danesh^{1,6,7,8,14}, Cathryn M. Lewis^{3,15}, Paola G. Bronson¹⁶, Hugh S. Markus¹⁷, Stephen Burgess^{1,6,18}, Adam S. Butterworth^{1,6,7,8}, Joanna M. M. Howson^{1*+}.

1. British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

2. Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK

3. Department of Medical & Molecular Genetics, King's College London, London, UK

4. Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London, UK

5. Rutherford Fund Fellow, Department of Public Health and Primary Care, University of Cambridge, UK

6. British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK

7. National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, UK

8. Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK

9. NHS Blood and Transplant-Oxford Centre, Level 2, John Radcliffe Hospital, Oxford, UK

10. Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK

11. NHS Blood and Transplant, Cambridge Biomedical Campus, Long Road, Cambridge, UK

- 26 12. Department of Haematology, University of Cambridge, Cambridge, UK
- 27 13. Wellcome Sanger Institute, Hinxton, UK
- 28 14. Department of Human Genetics, Wellcome Sanger Institute, Hinxton, UK
- 29 15. Social, Genetic and Developmental Psychiatry Centre, King's College London, London, UK
- 30 16. R&D Translational Biology, Biogen, Inc., Cambridge, MA, USA
- 31 17. Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
- 32 18. Medical Research Council Biostatistics Unit, Cambridge Institute of Public Health, University of
- 33 Cambridge, Cambridge, UK
- 34 *Correspondence to: Joanna M. M. Howson jmmh2@medschl.cam.ac.uk
- 35 ⁺ Current address: Novo Nordisk Research Centre Oxford, Innovation Building, Old Road Campus,
- 36 Roosevelt Drive, Oxford, UK.
- 37

38 Abstract

39 Proteins are the effector molecules of biology and are the target of most drugs. To identify proteins
40 and related pathways that may play a causal role in stroke pathogenesis, we used Mendelian
41 randomisation (MR). We tested potential causal effects of 308 plasma proteins (measured in 4,994
42 blood donors from the INTERVAL study) on stroke outcomes (derived from the MEGASTROKE
43 GWAS) in a two-sample MR framework and assessed whether these associations could be mediated
44 by cardiovascular risk factors. We extended the analysis to identify whether pharmacological
45 targeting of these proteins might have potential adverse side-effects or beneficial effects for other
46 conditions through Phenome-wide MR (Phe-MR) in UK Biobank.

47 MR showed an association between stroke and genetically predicted plasma levels of TFPI, IL6RA,
48 MMP12, CD40, TMPRSS5 and CD6 ($P \leq 1.62 \times 10^{-4}$). We identified six risk factors (atrial fibrillation,
49 body mass index, smoking, blood pressure, white matter hyperintensities and type 2 diabetes) that
50 were associated with stroke ($P \leq 0.0071$) using MR. The association of TFPI, IL6RA and TMPRSS5
51 with stroke could be mediated by these risk factors, such as body mass index, white matter
52 hyperintensity and atrial fibrillation. Thirty-six additional proteins were potentially causal for one or
53 more of these risk factors. The Phe-MR suggested that targeting TFPI could have potential beneficial
54 effects on other disorders of arteries and hyperlipidaemia in addition to stroke. Our results highlight
55 novel causal pathways and potential therapeutic targets for stroke.

56

57 Key Words

58 Mendelian Randomization; genetics; proteomics; stroke; cardiovascular disease; drug target;
59 Phenome-wide MR (PheMR)

60

61

62 Introduction

63 Stroke is the second leading cause of death worldwide, estimated to cause ~5.5 million deaths
 64 annually and is the leading cause of long-term disability, with a growing burden on global health ¹.
 65 Therefore, there is a need for new and improved treatments and prevention strategies for stroke. While
 66 conventional risk factors, such as hypertension ², account for ~50% of stroke risk, there remains a
 67 need to identify new risk factors, biomarkers and therapies for stroke³. In 2017, ~75% of FDA-
 68 approved drugs were targeted at human proteins⁴. Plasma proteins play a central role in a range of
 69 biological processes frequently dysregulated in diseases ⁵⁻⁸, and represent a major source of
 70 therapeutic targets for many indications ^{4,9,10}. In particular, plasma proteins are particularly relevant
 71 for circulatory diseases such as stroke as they are in physical contact with the blood vessels
 72 (compared to tissue-specific diseases, *e.g.* inflammatory bowel disease).

73 Genome-wide association studies (GWAS) of plasma protein levels have identified genetic variants
 74 that are associated with proteins, usually referred to as ‘protein quantitative trait loci (pQTLs)’ ¹¹⁻¹³,
 75 offering an opportunity to test the causal effect of potential drug targets on the human disease
 76 phenome using Mendelian randomization (MR) ^{14,15}. Briefly, MR can be thought of as nature’s
 77 randomized trial, by capitalising on the random allocation of genetic variants at conception to separate
 78 individuals into subgroups (one equivalent to placebo and the other to intervention in a randomized
 79 control trial, RCT) and so allows testing of the potential causal association of risk factors (*e.g.* plasma
 80 proteins) with disease outcomes (*e.g.* stroke) as confounders should also be randomised.

81 Here, we perform a two-sample MR to estimate the causal effects of plasma proteins on stroke, where
 82 we derived genetic instrumental variables of 308 circulating plasma proteins from 4,994 participants
 83 ¹⁶ and obtained genetic associations of stroke subtypes, (any stroke (AS), any ischemic stroke (IS),
 84 large-artery-stroke (LAS), cardio-embolic-stroke (CES) and small-vessel-stroke (SVS)) from the
 85 MEGASTROKE GWAS ¹⁷. Then, to verify the robustness of the proteins’ instrumental variables, we
 86 perform colocalization analyses. We evaluate the causal relationship of plasma proteins on stroke
 87 risk factors and assess potential safety effects of targeting the proteins for stroke therapy by
 88 performing a phenome-wide MR in UK Biobank GWASs ¹⁸.

89

90 **Methods**

91 The overall study design is illustrated in **Figure 1**. Details of the methods and study participants are
92 provided below.

93

94 **Proteomic profiling and quality control**

95 A subset of 4,994 blood donors at mean age of 61 years (SD 6.7 years) enrolled in the INTERVAL
96 BioResource¹⁶, were processed for proteomic profiling using the Olink Proseek® Multiplex platform
97 by 4 high-throughput, multiplex immunoassays: Inflammatory I (INF1), Cardiovascular II (CVD2),
98 Cardiovascular III (CVD3) and Neurology I (NEURO) (Olink Bioscience, Uppsala, Sweden). Each
99 panel enables the simultaneous measurement of 92 proteins through relative quantification using the
100 Proximity Extension Assay (PEA) Technology¹⁹, in which each pair of oligonucleotide-labelled
101 antibodies (“probes”) are allowed to bind to their respective target present in the sample and trigger
102 extension by DNA polymerase. DNA barcodes unique to each protein are then amplified and
103 quantified using a standard real-time polymerase chain reaction (PCR). Default pre-processing of
104 the proteomic data by Olink included applying median centring normalization between plates, where
105 the median is centred to the overall median for all plates, followed by log2 transformation to provide
106 normalised protein expression (NPX) values. Further details on the Olink proteomic data processing
107 can be found at <http://www.olink.com>. Probes were labelled using Uniprot identifiers, which we re-
108 mapped to HUGO gene name nomenclature for the (cis-) gene encoding the relevant protein. All
109 protein names and descriptions are provided in **Supplementary Table 1**.

110 Samples that failed standard Olink quality control metrics were removed. 4,902, 4,947, 4,987, and
111 4,660 samples passed quality control for the ‘INF1’, ‘CVD2’, ‘CVD3’ and ‘NEURO’ panels,
112 respectively. According to the manufacturer's recommendation, we also removed four proteins
113 (HAGH, BDNF, GDNF and CSF3) in the ‘NEURO’ panel and one protein (GDNF) in the ‘INF1’
114 panel due to high levels of missingness.

115

116 **Proteome GWAS**

117 The INTERVAL study¹⁶ was genotyped using the UK Biobank Affymetrix Axiom array
 118 (<http://www.ukbiobank.ac.uk/scientists-3/uk-biobank-axiom-array/>), and imputed to 1000 Genomes
 119 Phase 3-UK10K combined reference panel, employing the PBWT imputation algorithm²⁰. Genetic
 120 data for the ~5000 participants with Olink proteomic profiling were extracted to test for association of
 121 the genetic variants with plasma proteins. More details regarding the INTERVAL genetic data QC
 122 can be found here²¹. Within the ~5,000 participant subset, we removed six related individuals (those
 123 individuals with pairwise values of twice the kinship coefficient (PI_HAT) > 0.1875 (removing the
 124 individuals with the lowest call rate from each pair). The final imputed dataset was additionally
 125 filtered for imputation quality (only retaining variants with an info score > 0.4) and Hardy-Weinberg
 126 equilibrium (retaining variants with $P_{HWE} > 1 \times 10^{-4}$).
 127 354 proteins (of 363) that passed quality control were taken forward for the GWAS. Normalized
 128 protein levels ('NPX') were regressed on sex, age, plate, time from blood draw to processing (in
 129 days), season (as a categorical variable: 'Spring', 'Summer', 'Autumn', 'Winter'), and batch when
 130 appropriate. The residuals were then rank-inverse normalized. Linear regression of the rank-inversed
 131 normalized residuals on genotype was carried out in SNPTEST v.2.5.2²², with the first three
 132 components of multi-dimensional scaling as covariates to adjust for ancestry. Only proteins with at
 133 least one SNP with an association P -value passing the genome-wide significant threshold ($P \leq 5.0 \times 10^{-8}$)
 134 were kept, resulting in 308 proteins for MR analyses.

135

136 **Genetic variants associated with proteins**

137 For each plasma protein, cis- and trans- pQTLs from its corresponding GWAS were used as genetic
 138 instruments. We followed these steps to select pQTL instruments: (i) we obtained SNPs that were
 139 also tested in the MEGASTROKE GWAS of stroke outcomes (see below), (ii) we performed linkage
 140 disequilibrium (LD) clumping using PLINK 1.90 (www.cog-genomics.org/plink/1.9/)²³ to obtain

approximately independent SNPs for each protein. In brief, the LD clumping algorithm groups SNPs in LD ($r^2 \geq 0.1$ in 4,994 European ancestry participants from the INTERVAL study^{16,21}) within +/- 1MB of an index SNP (SNPs with association $P \leq 5 \times 10^{-8}$). Analyses assessing sensitivity to the $r^2 \geq 0.1$ LD threshold are detailed below. The algorithm loops through all index SNPs, beginning with the smallest P -value and only allowing each SNP to appear in one clump. The final output therefore contains the most significant protein-associated SNPs for each LD-based clump across the genome. We split pQTL variants into cis-pQTLs (+/-1MB window of the gene encoding the target protein) and trans-pQTLs (outside the +/-1MB window). We then performed MR in a two-step approach. Our primary analysis was restricted to cis-pQTLs. Having performed MR restricted to cis-pQTL only as IVs, we broadened the analysis to consider the effects of adding in trans-pQTLs as IVs. We estimated the variance of each protein explained by its IVs through calculating the R^2 ²⁴ and the strength of each IV by the F -statistic²⁵. Summary association statistics of all the instrumental variables (IVs) for the 15 significant proteins are provided in **Supplementary Table 2**.

To assess the robustness of the $r^2 \geq 0.1$ threshold for IV selection, we performed two additional sensitivity analyses (**Supplementary Table 11**) for proteins of interest to verify the robustness of MR causal relationship: 1) we performed conditional analysis to derive conditionally independent variants as IVs using the FINEMAP software package²⁶ with `--cond` flag; 2) we performed fine-mapping to obtain variants in the 95% credible set as IVs using FINEMAP software package²⁶ with `--sss` flag.

Genetic variants associated with stroke and its risk factors

The primary outcomes were the risk of stroke and its subtypes. Genetic association estimates for stroke outcomes were obtained from the MEGASTROKE consortium, a large-scale international collaboration launched by the International Stroke Genetics Consortium (ISGC). A detailed description of the study design and characteristics of study participants were provided in the original publication¹⁷. To reduce confounding by population stratification, we extracted estimates for the associations of the protein IVs with stroke and its subtypes restricted to individuals of European

ancestry (40,585 cases and 406,111 controls). The primary outcomes for this study were any stroke (including both ischemic and haemorrhagic stroke; AS, $N_{\text{cases}} = 40,585$), any ischemic stroke (IS, $N_{\text{cases}} = 34,217$), and the three etiologic ischemic stroke subtypes: large-artery stroke (LAS, $N_{\text{cases}} = 4,373$), cardio-embolic stroke (CES, $N_{\text{cases}} = 7,193$) and small-vessel stroke (SVS, $N_{\text{cases}} = 5,386$). Summary-level data (beta coefficients and standard errors) for the associations of the five stroke outcomes were obtained from the MEGASTROKE GWAS <http://www.megastroke.org/index.html>. The secondary outcomes we considered were stroke risk factors, including blood pressure (BP)²⁷, atrial fibrillation (AF)²⁸, type 2 diabetes (T2D)²⁹, white matter hyperintensity (WMH)³⁰, body mass index (BMI)³¹, alcohol consumption and smoking behaviour³². We used the same pQTLs as IVs for the secondary outcomes as for the primary outcomes. The SNP-outcome effects for all the above risk factors were obtained from previously published GWASs when available. **Table 1** provides full details of the data sources and sample size for these GWASs.

Phenome-wide MR (Phe-MR) analysis of 784 phenotypes for target proteins

We expanded the exploration of side-effects for the six stroke-associated proteins to include non-stroke phenotypes by performing Phe-MR analyses for a range of diseases. We used summary statistics for SNP-outcome effects calculated using the UK Biobank cohort ($N \leq 408,961$) by Zhou et al.³³, who performed GWAS using the Scalable and Accurate Implementation of GEneralized mixed model (SAIGE v.0.29) method³³ to account for unbalanced case-control ratios. They defined disease outcomes based on “PheCodes”, a system developed to organize International Classification of Diseases and Related Health Problems (ICD-9/-10) codes into phenotypic outcomes suitable for systematic genetic analysis of numerous disease traits^{18,33}. Outcomes with fewer than 500 cases were excluded due to statistical power, leaving 784 diseases for Phe-MR analyses (**Supplementary Table 8**). SNP-outcome associations were downloaded from SAIGE GWAS³³ (<https://www.leelabsg.org/resources>). pQTLs were derived from the same proteome GWAS as in the primary analysis with stroke subtypes.

Phe-MR findings can be interpreted as the risk/protective effect per-SD increase in the plasma protein level, same as with primary stroke outcomes. That is, if the effect direction of the additional indication is consistent with the effect direction in Stroke, the identified protein that is therapeutically targeted for the treatment of stroke may also be “beneficial” for the additional indication, and vice versa. MR causal effects are considered statistically significant at $P \leq 1.06 \times 10^{-5}$ (Bonferroni-adjusted for 6 proteins and 784 phenotypes: $0.05/6/784$).

Systematic MR screening for causal proteins of stroke and stroke risk factors

We used two-sample MR³⁴⁻³⁶ to estimate the associations between genetically-predicted protein levels and target outcomes (stroke, stroke risk factors, and potential adverse effects or additional indications). Two sample MR³⁷ is where the genetic associations with the risk factor are derived in one cohort (*e.g.* pQTLs from INTERVAL) and the association of these genetic variants with the outcome is tested in a second cohort (*e.g.* stroke GWAS from MEGASTROKE). Two-sample MR allows evaluation of causal effects using summary genetic association data, negating the need for individual participant data. The MR approach was based on the following assumptions: (i) the genetic variants used as instrumental variable (IV) are associated with target exposure, *i.e.*, protein levels; (ii) there are no unmeasured confounders of the associations between genetic variants and outcome; (iii) the genetic variants are associated with the outcome only through changes in the exposure, *i.e.*, no pleiotropy.

After extracting the association estimates between the variants and the exposures or the outcomes, we harmonized the direction of estimates by effect alleles, and applied the Wald’s ratio method to estimate the causal effects when there was only one IV available for target exposure. If more than one IV was available, we applied the inverse-variance weighting (IVW) method, either in a fixed-effect framework ($IVs \leq 3$) or in a multiplicative random-effect meta-analysis framework ($IVs > 3$)³⁴. We chose 3 as a cut-off for the random effects model, as with >3 variants, there is potential for some heterogeneity within instrumental variables. (The multiplicative random-effects model allows for heterogeneity between causal estimates targeted by the genetic variants by allowing over-dispersion

the regression model.) We also performed several sensitivity analyses to assess the robustness of our results to potential violations of the MR assumptions given these analyses have different assumptions for validity: (i) heterogeneity was estimated by Cochran Q test³⁴; (ii) horizontal pleiotropy was estimated using MR-Egger's intercept³⁸; (iii) influential outlier IVs due to pleiotropy were identified using MR Pleiotropy Residual Sum and Outlier (MR-PRESSO)³⁹; (iv) reverse MR was used to eliminate spurious results due to reverse causation. Additionally, the contamination mixture method⁴⁰, which can explicitly model multiple potential causal estimates and therefore infer multiple causal mechanisms associated with the same risk factor that affect the outcome to different degrees, was also used to calculate the MR estimates. Although these methods may have differing assumptions and statistical power, the rationale for using them is that if they give a similar conclusion, this provides greater certainty in inferring that any positive results are unlikely to be driven by violation of the MR assumptions.

Effects on binary outcomes (*i.e.*, stroke, AF, T2D, smoking initiation/cessation) are reported as odds ratios (ORs) with their 95% confidence intervals (CIs) scaled to a one standard deviation (SD) higher plasma protein level. Effects on quantitative outcomes (*i.e.*, BP, WMH, BMI) are reported as the effect size (95% CI) scaled to a 1-SD higher plasma protein levels. All statistical tests were two-sided and considered statistically significant at $P_{CausalEstimate} \leq 1.62 \times 10^{-4}$ (Bonferroni-adjusted for 308 proteins: $0.05/308 = 1.62 \times 10^{-4}$), $P_{Q-stat} \geq 0.05$, $P_{Egger-Intercept} \geq 0.05$ and $P_{GlobalTest} \geq 0.05$. The MR analyses were conducted using *MendelianRandomization* (Version: 0.4.2)³⁵, *TwoSampleMR* (Version: 0.4.22)³⁶ and *MR-PRESSO* (Version: 1.0)³⁹ packages in R 3.5.1 (R Foundation, www.R-project.org). Plots were generated using various R packages including *ggplot2* (Version: 3.2.0), *forestplot* (Version: 1.9), and *PheWAS* (Version: 0.99.5-4). We employed the same statistical analysis framework, incorporating the sensitivity analyses for all MR analyses.

Multi-trait colocalization analyses

As the instruments used in the current setting were identified based on their statistical associations with the protein level, we conducted another sensitivity analysis – colocalization, to investigate

whether the genetic associations with both protein and phenotypes shared the same causal variants.

We conducted colocalization analysis for each potential causal protein across multiple traits, including protein level and five stroke outcomes, to estimate the posterior probability (PP) of multiple traits sharing the same causal SNP simultaneously using a multi-trait colocalization (HyPrColoc) method⁴¹.

HyPrColoc extends the established coloc methodology⁴² by approximating the true posterior probability of colocalization with the posterior probability of colocalization at a single causal variant and a small number of related hypotheses. If all traits do not share a causal variant, HyPrColoc employs a novel branch-and-bound selection algorithm to identify subsets of traits that colocalize at distinct causal variants at the locus. We used uniform priors for the primary analysis. We also performed sensitivity analysis with non-uniform priors to assess the choice of priors, which used a conservative trait-level prior structure with $P=1 \times 10^{-4}$ (prior probability of a SNP being associated with one trait) and $\gamma=0.98$ (1-prior probability of a SNP being associated with an additional trait given that the SNP is associated with at least one other trait), *i.e.*, 1 in 500,000 variants are expected to be causal for two traits.

Variants within a $\pm 1\text{Mb}$ window around the pQTL with the smallest P -value, with imputation (INFO)-score ≥ 0.8 and minor allele frequency (MAF) ≥ 0.01 were included. All variants across each of the datasets were harmonized to the same effect alleles prior to colocalization analyses. We conducted the colocalization analysis using the ‘HyPrColoc’ R package⁴¹.

Results

Genetically determined plasma protein levels and risk of stroke

Three hundred and eight plasma proteins were tested for causal associations with stroke outcomes (**Figure 1**). As cis-pQTLs were considered to have a more direct and specific biological effect upon the protein (compared to trans-pQTLs)⁴³, we first performed MR analyses using only cis-pQTLs as instrumental variables and identified six putatively causal proteins with at least one stroke outcome ($P \leq 1.62 \times 10^{-4} = 0.05/308$ proteins; **Table 2, Figure 2 & Figure 3, Supplementary Figure 1**): TFPI (Tissue Factor Pathway Inhibitor), TMPRSS5 (Transmembrane Serine Protease 5), CD40 (B Cell Surface Antigen CD40), MMP12 (Matrix Metalloproteinase 12), IL6RA (Interleukin 6 Receptor), and CD6 (T-Cell Differentiation Antigen CD6). TFPI, CD40, IL6RA, and MMP12 were significantly associated with lower risk of any stroke and any ischemic stroke, while TMPRSS5 and CD6 was significantly associated with higher risk of any stroke. Among the ischemic stroke subtypes, genetic predisposition to upregulated TMPRSS5 was associated with higher risk of any ischemic stroke (OR per-1-SD higher plasma protein level [95%CI]=1.059[1.038, 1.08]; $P=1.36 \times 10^{-8}$) and Cardioembolic stroke (OR[95%CI]=1.089[1.045, 1.134]; $P=5.33 \times 10^{-5}$). Higher genetically predicted levels of both MMP12 (OR[95%CI]=0.793[0.73, 0.861]; $P=3.53 \times 10^{-8}$) and CD40 (OR[95% CI]= 0.795[0.723, 0.874]; $P=2.09 \times 10^{-6}$) were associated with lower risk of Large-artery stroke. Higher genetically predicted soluble IL6RA (and lower IL6R signalling⁴⁴) was associated with lower risk of Small-vessel stroke (OR[95% CI]= 0.939[0.909, 0.970]; $P=1.60 \times 10^{-4}$).

We extended the MR analyses to include trans-pQTLs as instrumental variables and identified nine additional proteins significantly associated with at least one stroke outcome ($P \leq 1.62 \times 10^{-4}$; **Supplementary Table 3**). However, seven proteins (VSIG2, EPHB4, Gal4, ICAM2, LIFR, SELE, and vWF), included instrumental variables from the *ABO* locus, which is well known to have pleiotropic effects. We note that the ABO protein has previously been identified as a genetic risk factor for stroke⁴⁵. Interestingly, both Bone Morphogenetic Protein 6 (BMP6) and Growth Differentiation Factor 2 (GDF2, also known as BMP9) were instrumented by *trans*-pQTLs located in the genetic regions of *KNG1* (Kininogen 1) and *F11* (Coagulation Factor XI). Both genes are essential for blood

coagulation and the latter has previously been reported to be a causal risk factor for stroke⁴⁶. GDF2 has also been found to have a causal role in pulmonary artery hypertension (PAH)⁴⁷. We therefore focused further analyses on the proteins with *cis* pQTL only (*i.e.*, TFPI, TMPRSS5, CD40, MMP12, IL6RA, CD6), as these associations with stroke are unlikely to be due to pleiotropy. Results of sensitivity analyses confirmed the robustness of the primary MR analyses. There was no evidence for heterogeneity in the association of any of the six proteins in **Supplementary Table 3** as measured by Cochran Q statistics ($P_{Q-stat} > 0.05$), and no indication that the instrumental variables had horizontal pleiotropy as assessed by MR-Egger intercept ($P_{Egger-Intercept} > 0.05$) or MR-PRESSO global pleiotropy test ($P_{GlobalTest} > 0.05$). All MR causal effect estimates adjusting for correlation of IVs' were consistent with the primary analyses (**Supplementary Table 10**). Moreover, MR causal estimates using IVs derived from conditionally independent variants and credible sets of variants from fine-mapping showed consistent results (**Supplementary Table 11 & 12**). There was no evidence of reverse causations (**Supplementary Table 13**).

Co-localization

We formally tested whether the associations of the variant with the protein levels used as IVs and the stroke outcome are shared for the six proteins using statistical colocalization analysis. We applied a Bayesian algorithm, Hypothesis Prioritization in multi-trait Colocalization (HyPrColoc), which allows for the assessment of colocalization across multiple complex traits simultaneously (**Methods**), to test whether the protein associations and stroke associations are shared. The association of the genetic variants selected as instrumental variables for four proteins (TFPI, TMPRSS5, CD40, and CD6) colocalized with the stroke associations (posterior probability (PP) ≥ 0.7) (**Supplementary Table 4, Supplementary Figure 2**) *i.e.*, the associations in these regions were likely due to the same underlying causal variants. The colocalization suggested the genetic variants associated with TFPI (pQTLs) were due to the same genetic variants underlying the association with all-stroke. Similarly, CD6 pQTLs colocalized with all-stroke genetic associations; CD40 pQTLs colocalized with the genetic associations for all-stroke, ischemic-stroke and large-artery-stroke; TMPRSS5 pQTLs

colocalized with all-stroke, ischemic-stroke and cardioembolic-stroke genetic associations. Notably, we found for TFPI, CD40, and CD6 that >80% of the posterior probability of colocalization of the primary genetic association with stroke and the respective protein levels were explained by a single variant (rs67492154, rs4810485, and rs2074227 for TFPI, CD40, and CD6, respectively). The colocalization evidence at MMP12, was less strong than with the other proteins, with colocalization PP>0.6 and there was no colocalization evidence for IL6RA with stroke, which could be due to violation of the single causal variant assumption of the HyprColoc method.

Characterizing the potential causal effects of stroke risk factors on stroke

To understand potential causal mechanisms between plasma proteins and stroke, we conducted mediation MR analyses for conventional stroke risk factors. First, we performed two-sample MR analyses to characterize the causal relationship of the stroke risk factors with all stroke outcomes. Second, we assessed the causal effects of the proteins on the highlighted risk factors.

For each of the six stroke risk factors we considered (*i.e.*, blood pressure (BP), atrial fibrillation (AF), type 2 diabetes (T2D), white matter hyper-intensity (WMH), body mass index (BMI), smoking behaviours and alcohol consumption), instrumental variables were derived from published GWAS summary statistics restricted to European populations (**Table 1 & Supplementary Table 5**). AF, T2D, smoking, increased systolic BP, diastolic BP, pulse pressure, WMH, and BMI significantly increased the risk of any stroke ($P \leq 0.05/7 = 0.007$, Bonferroni adjusted for seven risk factors; **Figure 4, Supplementary Table 6 & Supplementary Figure 3**). As expected, systolic BP exhibited the strongest effect of all the risk factors on any ischemic stroke and LAS (OR per-1-SD [95% CI]=1.68[1.57, 1.80] and 2.58[2.21, 3.01], respectively) and AF had a positive association with CES (OR[95% CI]: 2.04[1.92, 2.16]; $P = 2.72 \times 10^{-125}$). WMH increased risk of any stroke and SVS (1-SD increased in WMH was associated with 49% higher odds for SVS (OR[95% CI]=1.49[1.17, 1.9]; $P = 0.00147$). Both genetically determined higher T2D risk and smoking initiation were associated with increased risk of LAS and SVS; and genetically determined higher BMI was associated with

higher risk of LAS. No significant association was observed for alcohol consumption with any of the stroke outcomes ($P>0.05$).

Associations of genetically determined plasma protein levels with stroke risk factors

We performed MR of all 308 plasma proteins with the highlighted stroke risk factors (excluding alcohol consumption which was not associated with increased stroke risk in the above MR analyses). After multiple testing correction, 39 proteins instrumented with cis-pQTLs were significantly associated with at least one stroke risk factor ($P \leq 1.62 \times 10^{-4}$): 5 with Systolic BP; 7 with Diastolic BP; 7 with Pulse Pressure; 6 with AF; 4 with T2D; 9 with BMI; 3 with WMH; and 8 with smoking. There was no evidence of horizontal pleiotropy, and sensitivity analyses yielded consistent causal effect estimates (**Supplementary Table 14**).

Among the six stroke-associated proteins, three proteins were found to be significantly associated with one or more of the stroke risk factors (**Figure 5; Table 3; Supplementary Figure 4**). Of note, we found genetically predicted higher TFPI level was associated with lower WMH and lower BMI (a 0.06 SD lower WMH β [95% CI]= -0.06[-0.08, -0.04]; $P=7.15 \times 10^{-10}$ and a 0.013 SD lower BMI β [95% CI]= -0.013[-0.019, -0.007]; $P=3.56 \times 10^{-5}$ per-SD higher TFPI; **Supplementary Table 7**). We thus inferred that the association between TFPI and stroke could be partially mediated by BMI and WMH. Genetically determined higher TMPRSS5 levels were associated with higher risk of AF (OR[95% CI]: 1.03[1.016, 1.045]; $P=2.15 \times 10^{-5}$). Together with the causal relationship of AF and cardioembolic stroke, we can also infer that AF is a possible mediator on the effect of TMPRSS5 on cardioembolic stroke. Genetically higher IL6RA levels were associated with a 4.1% lower risk of AF (OR[95% CI]: 0.96[0.95, 0.97]; $P=2.55 \times 10^{-18}$). All the effect directions of these associations of proteins with risk factors were consistent with those of the proteins with stroke, indicating that these risk factors may be potential mediators of the protein-stroke associations.

Among the 39 proteins that were associated with at least one stroke risk factor, 36 were found to be associated with the risk factors but not stroke outcome (**Supplementary Table 14**). For example,

genetically determined Fibroblast Growth Factor 5 (FGF5) level was associated with higher risk of AF (OR=1.056 per SD higher FGF5); each SD higher genetically determined Glypican 5 (GPC5) was associated with higher risk of T2D (OR=1.02); each SD higher in genetically determined Scavenger Receptor Class F Member 2 (SCARF2) was associated with a 0.062-SD higher WMH. We found that higher genetically determined Alpha-L-Iduronidase (IDUA) and Sialic Acid-Binding Ig-Like Lectin 9 (SIGLEC9) were both associated with lower BMI. Higher genetically determined Serine Protease 27 (PRSS27) was associated with higher SBP, higher DBP and higher PP, while higher genetically determined levels of Neurocan (NCAN) were associated with lower risk of T2D (OR=0.76) and 0.07-SD lower SBP.

Phenome-wide MR (Phe-MR) analysis of stroke-associated proteins in UK Biobank

To assess whether the six stroke-associated proteins have either beneficial or deleterious effects for other indications, we performed a broader MR screen of 784 diseases and traits in UK Biobank (Supplementary Table 8). Our Phe-MR results can be interpreted as a per-SD increase in genetically determined plasma protein level that leads to an higher or lower odds of a given disease or trait. If the effect direction of the protein on the disease or trait is the same as on stroke, the effect is considered “beneficial” and “deleterious” otherwise. Overall, 34 significant associations were identified ($P \leq 0.05/6/784 = 1.06 \times 10^{-5}$), of which 21 (61.7%) were in the same direction as the stroke association (Supplementary Table 9).

Notably, genetically higher levels of plasma TFPI were not only associated with lower risk of stroke, but also lower risk of other diseases involving the circulatory system (cerebrovascular disease, other disorders of arteries), metabolic traits (hyperlipidemia and hypercholesterolemia, disorders of lipid metabolism) and digestive system disorders (acute gastritis); however, they were also associated with higher risk of excessive or frequent menstruation (Figure 6 & Supplementary Figure 5). Genetically higher levels of plasma TMPRSS5 were associated with higher risk of cardioembolic stroke, as well as protein-calorie malnutrition (metabolic trait) (Figure 6 & Supplementary Figure 5). All the significant associations for CD40, including haemoptysis and abnormal sputum

(respiratory system) were consistent with the effect direction of that with stroke. Effects of IL6RA on risk of diseases on circulatory system disorders (ischemic heart disease, cardiac dysrhythmias, atrial fibrillation and flutter, coronary atherosclerosis, angina pectoris, abdominal aortic aneurysm) and musculoskeletal disease (other inflammatory spondylopathies) were consistent with that on risk of stroke; but had inverse effects on dermatologic symptoms (*e.g.* cellulitis and abscess of arm/foot), digestive system (*e.g.* cholelithiasis) and chronic renal failure [CKD] (**Supplementary Figure 6 & Supplementary Table 9**). Genetically predicted CD6 was associated with alcoholic liver damage and degeneration of intervertebral disc (musculoskeletal system) but in the inverse direction to stroke. Summary results of the primary and sensitivity MR analyses for all the 784 phenotypes are provided in **Supplementary Table 9**.

Discussion

Based on genetic data for 308 proteins involved in cardiovascular disease, inflammation and neurological processes from ~5000 individuals¹⁶, our study provides robust evidence that six proteins (TFPI, TMPRSS5, CD40, MMP12, IL6RA, and CD6) are causally associated with stroke. We showed that AF, systolic and diastolic BP, BMI, T2D, WMH and smoking were causally associated with risk of any stroke (and some ischemic stroke subtypes), demonstrating a key role of the risk factors in the pathogenesis of stroke consistent with classical epidemiological data⁴⁸⁻⁵⁶. We found the associations of TFPI, IL6RA, and TMPRSS5 with stroke were likely to be mediated by one or more of these risk factors. In addition, we showed that 36 additional proteins were causal for these risk factors. Finally, the Phe-MR highlighted additional beneficial indications of therapeutically targeting the six stroke-associated proteins and importantly, indicated few potential safety concerns. Although, as many of the phenotypes tested are not independent, the definition of significance used here might be too conservative (Bonferroni-corrected P -value adjusted for the number of proteins tested (six) and the total number of phenotypes (784) ($P=0.05/6/784=1.06\times 10^{-5}$).

Tissue factor pathway inhibitor (TFPI) is primarily secreted by endothelial cells and is an anticoagulant that acts on the clotting cascade⁵⁷. Observational studies showed that lower levels of free TFPI were associated with higher risk of ischemic stroke⁵⁸ and higher risk of first and recurrent venous thrombosis⁵⁹, while inhibition of TFPI showed to be an effective treatment of bleeding associated with hemophilia⁶⁰. Consistent with this, we provided genetic evidence for directionally consistent effects of TFPI on multiple ischemic traits, such as ischemic stroke and ischemic heart disease, and opposite effects on haemorrhagic traits (*e.g.*, gastrointestinal haemorrhage, $P=5.23\times 10^{-5}$; excessive or frequent menstruation in females, $P=2.70\times 10^{-10}$). We also showed that higher levels of TFPI were associated with lower BMI and WMH (**Figure 5**), and lower risk of hyperlipidemia, specifically hypercholesterolemia (**Figure 6**), suggesting that the pathways through which TFPI influences stroke risk might go beyond anticoagulation, *e.g.*, inflammation or atherosclerotic changes. Animal studies^{60,61} provide supporting evidence that TFPI has a role in attenuating arterial thrombus formation and atherosclerosis development. Future studies of TFPI in cardiovascular diseases

focusing on the role of TFPI activity and different TFPI isoforms in the development of atherogenesis could provide further insights.

TMPRSS5 (Transmembrane Protease Serine 5, also known as Spinesin) is a member of the Type II Transmembrane Serine Protease Family (TTSPs)⁶². For example, TMPRSS10 (Corin), one member of the TTSPs, has been reported to be involved in cardiac conduction and myometrial relaxation and contraction pathways in regulating blood pressure and promoting natriuresis, diuresis and vasodilation⁶³. Unlike Corin, the function of TMPRSS5 on cardiovascular systems is poorly understood. Human *TMPRSS5* mRNA has been shown to be expressed in the brain and the protein is predominantly expressed in neurons, in their axons in the spinal cord⁶⁴. A mouse model with mutant TMPRSS5 had reduced proteolytic activity and suggested a role in hearing loss⁶⁵. We were unable to find other studies that implicate TMPRSS5 in cardiovascular disease, both for any ischemic stroke and cardioembolic stroke, an effect that might be mediated by risk of atrial fibrillation (**Figure 4**). Furthermore, Phe-MR analysis revealed suggestive additional beneficial effects when targeted at TMPRSS5, *e.g.*, reduced risk of Parkinson's disease ($P=2.15 \times 10^{-5}$) and left bundle branch block ($P=1.43 \times 10^{-5}$). Taken together, TMPRSS5 represents a potentially promising therapeutic target for atrial fibrillation and cardioembolic stroke, and further research is warranted to decipher the mechanism through which it protects against cardiovascular and neurological diseases.

In addition, we have identified CD6, a lymphocyte surface receptor, associated with increased risk of any stroke. CD6 is a pan T cell marker^{66,67}, and involved in T cell proliferation and activation through its interaction with ALCAM (activated leukocyte cell adhesion molecule)⁶⁸. The interaction of CD6 and ALCAM is required to promote an inflammatory T cell response⁶⁹. Interestingly, Smedbakken L *et al*⁷⁰ found that acute ischemic stroke patients with upregulated ALCAM at admission had a significantly poorer survival rate ($P<0.001$). Given this interaction and that the recruitment of leukocytes and platelets is widely regarded as a pivotal step in the inflammatory response associated with cerebral ischemia^{71,72}, together with our finding that CD6 is associated with stroke, further investigation of CD6 in the context of stroke is justified.

Our study not only identified potentially novel targets (*i.e.* TFPI, TMPRSS5 and CD6) for stroke, but also validated proteins that had been identified as causally associated with cardiovascular diseases in previous proteome MR studies ^{11,46,73}, *e.g.* CD40, MMP12 and IL6RA. Genetic variants in the *IL6R* region are associated with risk of inflammatory related diseases ⁴⁴, including coronary heart disease ⁷⁴, stroke ⁷³, atrial fibrillation ⁷⁵ and rheumatoid arthritis ⁷⁶. Moreover, IL6R is the target of an FDA-approved therapy (Tocilizumab) for the treatment of several diseases, *e.g.*, rheumatoid arthritis and systemic juvenile idiopathic arthritis. Phase II clinical trials testing tocilizumab for the therapy of Non-ST Elevation Myocardial Infarction have reported promising results ⁷⁷ and a phase III clinical trial testing Ziltivekimab in cardiovascular disease and chronic kidney disease has recently started (NCT05021835).

To avoid violating the MR assumptions, we performed various sensitivity analyses. We used LD clumping at R^2 0.1 for pQTLs with $P5.0 \times 10^{-8}$ to choose instruments for each of plasma protein level. However, concern ⁷⁸ has been raised about the independency of the variants used as instrumental variables leading to violation of the InSIDE (instrument strength independent of direct effect) assumption of the MR-Egger method used. Therefore, we performed several sensitivity analyses to validate the robustness of the instrumental variables used in the MR analysis. Firstly, we performed MR analyses adjusting for the correlation of the variants used and obtained consistent and similar causal effect estimates to those obtained without adjusting for the correlation (**Supplementary Table 10**). Secondly, we performed conditional analysis and fine-mapping analysis to obtain instrumental variables for the six potential causal proteins and we obtained consistent MR results (**Supplementary Table 12 & Supplementary Figure 7**). Finally, colocalization analyses across the genetic associations with protein levels and stroke outcomes showed they were likely to have shared causal variants across these traits, supporting the validity of instrumental variables and the causal protein associations (**Supplementary Table 4**).

The Olink assay¹⁹ used in our study measures the bulk concentration of protein in plasma. However, because this assay cannot distinguish free from bound protein or active from inactive, only limited mechanistic insights can be made. Due to the limited capture of human proteome (1.5% of all known

proteins), we could not evaluate the effects of all proteins within the same family or all proteins encoded within the same genomic region. For instance, we found that TMPRSS5 was a potential novel drug target for cardioembolic stroke, while other proteins in the Type II Transmembrane Serine Protease Family (TTSPs) that play crucial roles in cardiac functions^{62,79} could not be evaluated. Thus, a targeted study of the TTSP family is warranted to comprehensively evaluate their effects in cardiovascular and neurological traits.

Our results highlight potential targets of future therapies for stroke outcomes and illustrates the relevance of proteomics in identifying drug targets. Further research is necessary to assess the viability of the six identified proteins as drug targets for stroke treatment. Additional drug targets may be uncovered as more comprehensive proteomics platforms become available and more diverse non-European ancestry populations are increasingly studied. Finally, there is an increasing need for similarly comprehensive proteomics across different tissues and organs to evaluate tissue- or organ-specific protein effects.

Funding

This work and LC were funded by a program grant from the British Heart Foundation (RG/16/4/32218). PS is supported by a Rutherford Fund Fellowship from the Medical Research Council (MR/S003746/1). BP and SK are funded by a British Heart Foundation Programme grant (RG/18/13/33946). EY-D was funded by the Isaac Newton Trust / Wellcome Trust ISSF / University of Cambridge Joint Research Grants Scheme. SB is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (204623/Z/16/Z). JMMH was funded by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) [*]. CML is funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. HSM is supported by a NIHR Senior Investigator award, and his work is supported by the Cambridge Universities NIHR Comprehensive Biomedical Research Centre. JD holds a British Heart Foundation Professorship and a NIHR Senior Investigator Award [*].

*The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Acknowledgements

Participants in the INTERVAL randomised controlled trial were recruited with the active collaboration of NHS Blood and Transplant England (www.nhsbt.nhs.uk), which has supported field work and other elements of the trial. DNA extraction and genotyping were co-funded by the National Institute for Health Research (NIHR), the NIHR BioResource (<http://bioresource.nihr.ac.uk>) and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) [*]. The Olink® Proteomics assays were funded by Biogen, Inc. (Cambridge, MA, US). The academic coordinating centre for INTERVAL was supported by core funding from the: NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024), UK Medical Research Council (MR/L003120/1), British Heart Foundation (SP/09/002; RG/13/13/30194; RG/18/13/33946) and NIHR Cambridge BRC (BRC-1215-20014) [*] and funding from the EC-Innovative Medicines

Initiative (BigData@Heart). A complete list of the investigators and contributors to the INTERVAL trial is provided in reference [**]. The academic coordinating centre would like to thank blood donor centre staff and blood donors for participating in the INTERVAL trial.

This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome.

*The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

**Di Angelantonio E, Thompson SG, Kaptoge SK, Moore C, Walker M, Armitage J, Ouwehand WH, Roberts DJ, Danesh J, INTERVAL Trial Group. Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors. *Lancet*. 2017 Nov 25;390(10110):2360-2371.

Author contributions

L.C. performed the analyses and wrote the initial draft of the manuscript. J.M.M.H. designed and supervised the project. J.E.P, B.P, E.P provided data and analytical support. All authors contributed to the data preparation and critically reviewed the manuscript.

Competing interests

JMMH, LC, MT and EY-D became full time employees of Novo Nordisk Ltd during the drafting of this manuscript. JD reports grants, personal fees and non-financial support from Merck Sharp & Dohme (MSD), grants, personal fees and non-financial support from Novartis, grants from Pfizer and grants from AstraZeneca outside the submitted work. JD sits on the International Cardiovascular and

Metabolic Advisory Board for Novartis (since 2010); the Steering Committee of UK Biobank (since 2011); the MRC International Advisory Group (ING) member, London (since 2013); the MRC High Throughput Science ‘Omics Panel Member, London (since 2013); the Scientific Advisory Committee for Sanofi (since 2013); the International Cardiovascular and Metabolism Research and Development Portfolio Committee for Novartis; and the Astra Zeneca Genomics Advisory Board (2018). ASB reports institutional grants from AstraZeneca, Bayer, Biogen, BioMarin, Bioverativ, Merck, Novartis and Sanofi and personal fees from Novartis. PB is a full-time employee of Biogen Inc. CML sits on the Scientific Advisory Board for Myriad Neuroscience.

568 References

- 569 1. Feigin, V.L. *et al.* Global, regional, and national burden of neurological disorders,
570 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The*
571 *Lancet Neurology* **18**, 459-480 (2019).
- 572 2. Ettehad, D. *et al.* Blood pressure lowering for prevention of cardiovascular disease
573 and death: a systematic review and meta-analysis. *The Lancet* **387**, 957-967 (2016).
- 574 3. Hankey, G.J. Stroke. *The Lancet* **389**, 641-654 (2017).
- 575 4. Santos, R. *et al.* A comprehensive map of molecular drug targets. *Nat Rev Drug*
576 *Discov* **16**, 19-34 (2017).
- 577 5. Olszewski, A.J. & Szostak, W.B. Homocysteine content of plasma proteins in ischemic
578 heart disease. *Atherosclerosis* **69**, 109-13 (1988).
- 579 6. Robins, S.J., Lyass, A., Brocia, R.W., Massaro, J.M. & Vasan, R.S. Plasma lipid transfer
580 proteins and cardiovascular disease. The Framingham Heart Study. *Atherosclerosis*
581 **228**, 230-6 (2013).
- 582 7. Goetzl, E.J. *et al.* Altered lysosomal proteins in neural-derived plasma exosomes in
583 preclinical Alzheimer disease. *Neurology* **85**, 40-7 (2015).
- 584 8. Feldreich, T. *et al.* Circulating proteins as predictors of cardiovascular mortality in
585 end-stage renal disease. *Journal of nephrology* **32**, 111-119 (2019).
- 586 9. Hauser, A.S. *et al.* Pharmacogenomics of GPCR Drug Targets. *Cell* **172**, 41-54 e19
587 (2018).
- 588 10. Ursu, O., Glick, M. & Oprea, T. Novel drug targets in 2018. *Nat Rev Drug Discov*
589 (2019).
- 590 11. Sun, B.B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73-79
591 (2018).
- 592 12. Yao, C. *et al.* Genome-wide mapping of plasma protein QTLs identifies putatively
593 causal genes and pathways for cardiovascular disease. *Nat Commun* **9**, 3268 (2018).
- 594 13. Emilsson, V. *et al.* Co-regulatory networks of human serum proteins link genetics to
595 disease. *Science* **361**, 769-773 (2018).
- 596 14. Smith, G.D. Mendelian randomization for strengthening causal inference in
597 observational studies: application to gene-environment interactions. *Perspectives*
598 *on Psychological Science* **5**, 527-545 (2010).
- 599 15. Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal
600 inference in epidemiological studies. *Human molecular genetics* **23**, R89-R98 (2014).
- 601 16. Di Angelantonio, E. *et al.* Efficiency and safety of varying the frequency of whole
602 blood donation (INTERVAL): a randomised trial of 45 000 donors. *The Lancet* **390**,
603 2360-2371 (2017).
- 604 17. Malik, R. *et al.* Multi-ancestry genome-wide association study of 520,000 subjects
605 identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet* **50**, 524-537
606 (2018).
- 607 18. Denny, J.C. *et al.* Systematic comparison of phenome-wide association study of
608 electronic medical record data and genome-wide association study data. *Nat*
609 *Biotechnol* **31**, 1102-10 (2013).
- 610 19. Assarsson, E. *et al.* Homogenous 96-plex PEA immunoassay exhibiting high sensitivity,
611 specificity, and excellent scalability. *PLoS one* **9**, e95192 (2014).
- 612 20. Durbin, R. Efficient haplotype matching and storage using the positional Burrows-
613 Wheeler transform (PBWT). *Bioinformatics* **30**, 1266-1272 (2014).

- 614 21. Astle, W.J. *et al.* The allelic landscape of human blood cell trait variation and links to
615 common complex disease. *Cell* **167**, 1415-1429. e19 (2016).
- 616 22. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint
617 method for genome-wide association studies by imputation of genotypes. *Nature*
618 *Genetics* **39**, 906-913 (2007).
- 619 23. Chang, C.C. *et al.* Second-generation PLINK: rising to the challenge of larger and
620 richer datasets. *Gigascience* **4**, 7 (2015).
- 621 24. Pierce, B.L., Ahsan, H. & Vanderweele, T.J. Power and instrument strength
622 requirements for Mendelian randomization studies using multiple genetic variants.
623 *Int J Epidemiol* **40**, 740-52 (2011).
- 624 25. Palmer, T.M. *et al.* Using multiple genetic variants as instrumental variables for
625 modifiable risk factors. *Statistical Methods in Medical Research* **21**, 223-242 (2012).
- 626 26. Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from
627 genome-wide association studies. *Bioinformatics* **32**, 1493-1501 (2016).
- 628 27. Surendran, P. *et al.* Discovery of rare variants associated with blood pressure
629 regulation through meta-analysis of 1.3 million individuals. *Nature Genetics* (2020).
- 630 28. Nielsen, J.B. *et al.* Biobank-driven genomic discovery yields new insight into atrial
631 fibrillation biology. *Nat Genet* **50**, 1234-1239 (2018).
- 632 29. Mahajan, A. *et al.* Fine-mapping type 2 diabetes loci to single-variant resolution using
633 high-density imputation and islet-specific epigenome maps. *Nat Genet* **50**, 1505-
634 1513 (2018).
- 635 30. Persyn, E. *et al.* Genome-wide association study of MRI markers of cerebral small
636 vessel disease in 42,310 participants. *Nature Communications* **11**, 2175 (2020).
- 637 31. Pulit, S.L. *et al.* Meta-analysis of genome-wide association studies for body fat
638 distribution in 694 649 individuals of European ancestry. *Hum Mol Genet* **28**, 166-174
639 (2019).
- 640 32. Liu, M. *et al.* Association studies of up to 1.2 million individuals yield new insights
641 into the genetic etiology of tobacco and alcohol use. *Nat Genet* **51**, 237-244 (2019).
- 642 33. Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample
643 relatedness in large-scale genetic association studies. *Nat Genet* **50**, 1335-1341
644 (2018).
- 645 34. Burgess, S., Butterworth, A. & Thompson, S.G. Mendelian Randomization Analysis
646 With Multiple Genetic Variants Using Summarized Data. *Genetic Epidemiology* **37**,
647 658-665 (2013).
- 648 35. Yavorska, O.O. & Burgess, S. MendelianRandomization: an R package for performing
649 Mendelian randomization analyses using summarized data. *International Journal of*
650 *Epidemiology* **46**, 1734-1739 (2017).
- 651 36. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across
652 the human phenome. *Elife* **7**(2018).
- 653 37. Lawlor, D.A. Commentary: Two-sample Mendelian randomization: opportunities and
654 challenges. *International journal of epidemiology* **45**, 908 (2016).
- 655 38. Bowden, J., Smith, G.D. & Burgess, S. Mendelian randomization with invalid
656 instruments: effect estimation and bias detection through Egger regression.
657 *International Journal of Epidemiology* **44**, 512-525 (2015).
- 658 39. Verbanck, M., Chen, C.-y., Neale, B. & Do, R. Detection of widespread horizontal
659 pleiotropy in causal relationships inferred from Mendelian randomization between
660 complex traits and diseases. *Nature genetics* **50**, 693-698 (2018).

- 661 40. Burgess, S., Foley, C.N., Allara, E., Staley, J.R. & Howson, J.M.M. A robust and
662 efficient method for Mendelian randomization with hundreds of genetic variants.
663 *Nature Communications* **11**, 376 (2020).
- 664 41. Foley, C.N. *et al.* A fast and efficient colocalization algorithm for identifying shared
665 genetic risk factors across multiple traits. *Nat Commun* **12**, 764 (2021).
- 666 42. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic
667 association studies using summary statistics. *PLoS Genet* **10**, e1004383 (2014).
- 668 43. Zheng, J. *et al.* Phenome-wide Mendelian randomization mapping the influence of
669 the plasma proteome on complex diseases. *Nat Genet* **52**, 1122-1131 (2020).
- 670 44. Ferreira, R.C. *et al.* Functional IL6R 358Ala Allele Impairs Classical IL-6 Receptor
671 Signaling and Influences Risk of Diverse Inflammatory Diseases. *PLOS Genetics* **9**,
672 e1003444 (2013).
- 673 45. Williams, F.M. *et al.* Ischemic stroke is associated with the ABO locus: the EuroCLOT
674 study. *Ann Neurol* **73**, 16-31 (2013).
- 675 46. Chong, M. *et al.* Novel Drug Targets for Ischemic Stroke Identified Through
676 Mendelian Randomization Analysis of the Blood Proteome. *Circulation* (2019).
- 677 47. Hodgson, J. *et al.* Characterization of GDF2 Mutations and Levels of BMP9 and
678 BMP10 in Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med* **201**, 575-585
679 (2020).
- 680 48. Wolf, P.A., Abbott, R.D. & Kannel, W.B. Atrial fibrillation as an independent risk
681 factor for stroke: the Framingham Study. *Stroke* **22**, 983-988 (1991).
- 682 49. Yang, X.-M. *et al.* Atrial fibrillation known before or detected after stroke share
683 similar risk of ischemic stroke recurrence and death. *Stroke* **50**, 1124-1129 (2019).
- 684 50. Lawes, C.M., Bennett, D.A., Feigin, V.L. & Rodgers, A. Blood pressure and stroke: an
685 overview of published reviews. *Stroke* **35**, 776-785 (2004).
- 686 51. Kannel, W.B., Wolf, P.A., Verter, J. & McNamara, P.M. Epidemiologic assessment of
687 the role of blood pressure in stroke: the Framingham study. *Jama* **276**, 1269-1278
688 (1996).
- 689 52. Mäntylä, R. *et al.* Magnetic resonance imaging white matter hyperintensities and
690 mechanism of ischemic stroke. *Stroke* **30**, 2053-2058 (1999).
- 691 53. Mitchell, A.B. *et al.* Obesity Increases Risk of Ischemic Stroke in Young Adults. *Stroke*
692 **46**, 1690-1692 (2015).
- 693 54. Kivimäki, M. *et al.* Overweight, obesity, and risk of cardiometabolic multimorbidity:
694 pooled analysis of individual-level data for 120 813 adults from 16 cohort studies
695 from the USA and Europe. *The Lancet Public Health* **2**, e277-e285 (2017).
- 696 55. Janghorbani, M. *et al.* Prospective Study of Type 1 and Type 2 Diabetes and Risk of
697 Stroke Subtypes. *The Nurses' Health Study* **30**, 1730-1735 (2007).
- 698 56. Rost, N.S. *et al.* White matter hyperintensity volume is increased in small vessel
699 stroke subtypes. *Neurology* **75**, 1670-1677 (2010).
- 700 57. Broze Jr, G.J. Tissue factor pathway inhibitor. *Thrombosis and haemostasis* **73**, 090-
701 093 (1995).
- 702 58. He, M. *et al.* Observation on tissue factor pathway and some other coagulation
703 parameters during the onset of acute cerebrocardiac thrombotic diseases.
704 *Thrombosis research* **107**, 223-228 (2002).
- 705 59. Hoke, M. *et al.* Tissue factor pathway inhibitor and the risk of recurrent venous
706 thromboembolism. *Thrombosis and haemostasis* **94**, 787-790 (2005).

60. Waters, E.K. *et al.* Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. *Blood* **117**, 5514-5522 (2011).
61. Westrick, R.J. *et al.* Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. *Circulation* **103**, 3044-3046 (2001).
62. Bugge, T.H., Antalis, T.M. & Wu, Q. Type II transmembrane serine proteases. *J Biol Chem* **284**, 23177-81 (2009).
63. Knappe, S., Wu, F., Masikat, M.R., Morser, J. & Wu, Q. Functional analysis of the transmembrane domain and activation cleavage of human corin design and characterization of a soluble corin. *Journal of Biological Chemistry* **278**, 52363-52370 (2003).
64. Yamaguchi, N., Okui, A., Yamada, T., Nakazato, H. & Mitsui, S. Spinesin/TMPRSS5, a novel transmembrane serine protease, cloned from human spinal cord. *J Biol Chem* **277**, 6806-12 (2002).
65. Guipponi, M. *et al.* An integrated genetic and functional analysis of the role of type II transmembrane serine proteases (TMPRSSs) in hearing loss. *Hum Mutat* **29**, 130-41 (2008).
66. Carrasco, E. *et al.* Human CD6 Down-Modulation following T-Cell Activation Compromises Lymphocyte Survival and Proliferative Responses. *Front Immunol* **8**, 769 (2017).
67. Hernández, P., Moreno, E., Aira, L.E. & Rodríguez, P.C. Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab. *Curr Drug Targets* **17**, 666-77 (2016).
68. Zimmerman, A.W. *et al.* Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. *Blood* **107**, 3212-3220 (2006).
69. Gimferrer, I. *et al.* Relevance of CD6-Mediated Interactions in T Cell Activation and Proliferation. *The Journal of Immunology* **173**, 2262-2270 (2004).
70. Smedbakken, L. *et al.* Activated Leukocyte Cell Adhesion Molecule and Prognosis in Acute Ischemic Stroke. *Stroke* **42**, 2453-2458 (2011).
71. Jin, R., Yang, G. & Li, G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. *J Leukoc Biol* **87**, 779-89 (2010).
72. Elkind, M.S. Inflammatory mechanisms of stroke. *Stroke* **41**, S3-8 (2010).
73. Georgakis, M.K. *et al.* Genetically determined levels of circulating cytokines and risk of stroke: role of monocyte chemoattractant protein-1. *Circulation* **139**, 256-268 (2019).
74. Swerdlow, D.I. *et al.* The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. *Lancet* **379**, 1214-24 (2012).
75. Schnabel, R.B. *et al.* Large-scale candidate gene analysis in whites and African Americans identifies IL6R polymorphism in relation to atrial fibrillation: the National Heart, Lung, and Blood Institute's Candidate Gene Association Resource (CARE) project. *Circulation: Cardiovascular Genetics* **4**, 557-564 (2011).
76. Eyre, S. *et al.* High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. *Nature genetics* **44**, 1336-1340 (2012).
77. Ueland, T. *et al.* Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction. *Open heart* **5**, e000765 (2018).
78. Plump, A. & Davey Smith, G. Identifying and Validating New Drug Targets for Stroke and Beyond: Can Mendelian Randomization Help? (Am Heart Assoc, 2019).

754 79. Szabo, R. *et al.* Type II transmembrane serine proteases. *Thromb Haemost* **90**, 185-
755 93 (2003).
756

757

Figures (in separate file)

Figure 1. Overview of MR analyses.

Figure 2. Venn diagram of identified potential causal proteins for stroke subtypes.

Figure 3. Effects of six potential causal proteins on stroke subtypes.

Figure 4. Causal effects of risk factors on stroke subtypes.

Figure 5. Effect sizes (Z-score) of six potential causal proteins on stroke subtypes and causal risk factors for stroke.

Figure 6. Forest plots illustrating the potential on-target side-effects associated with causal proteins revealed by Phe-MR analysis for TFPI (A) and TMPRSS5 (B).

Tables (in separate file)

Table 1. Data sources for the Mendelian Randomization analysis in current study.

Table 2. Summary of significant proteins (biomarkers) representing potential causal factors for stroke and subtypes.

Table 3. Stroke risk factors are potential mediators of stroke associated proteins and stroke.

Supplementary Figures (in separate file)

Supplementary Tables (in separate file)

Figures

Figure 1. Overview of MR analyses.

Four O-link panels were used to measure plasma proteins in a subset of ~5000 samples from the INTERVAL study¹⁶. Genetic variants associated with plasma protein levels were identified based on results from their corresponding GWAS. These genetic variants were then used as proxies for the protein level and tested their relationship with stroke was tested used data from the MEGASTROKE consortium¹⁷ for stroke outcomes (Primary MR), with conventional stroke risk factors (Secondary MR), and with 784 phenotypes (Phe-MR) in UK Biobank to test a broad spectrum of potential effects of hypothetical therapeutic agents for stroke.

Figure 2. Venn diagram of identified potential causal proteins for stroke subtypes.

Figure 3. Effects of six potential causal proteins on stroke subtypes.

OR: Odds ratio; I^2 : heterogeneity. CD40: B Cell Surface Antigen CD40; TFPI: Tissue Factor

Pathway Inhibitor; MMP12: Matrix Metalloproteinase 12; IL6RA: Interleukin 6 Receptor Subunit

Alpha; TMPRSS5: Transmembrane Serine Protease 5; CD6: T-Cell Differentiation Antigen CD6.

Figure 4. Causal effects of risk factors on stroke subtypes.

I^2 : heterogeneity. SBP = Systolic Blood Pressure; AF = Atrial Fibrillation; WMH = White Matter Hyperintensity; T2D = Type 2 Diabetes; BMI = Body Mass Index; Smoking = Smoking Initiation.

Figure 5. Effect sizes (Z-score) of six potential causal proteins on stroke subtypes and causal risk

factors for stroke.

Colours in each lattice of the heatmap represent the effect size (Z-score), with genetically predicted increased protein level associated with higher risk of outcomes coloured in brown and lower risk of outcomes coloured in blue. The darker the colour the larger the effect size.

* indicates that the causal association is significant, which passed Bonferroni correction of

$P_{causalEstimate_IVW} \leq 0.05/308 = 1.61 \times 10^{-4}$ and passed sensitivity tests with $P_{Qstat} \geq 0.05$ and $P_{EggerIntercept} \geq 0.05$.

Figure 6. Forest plots illustrating the potential on-target side-effects associated with causal proteins

revealed by Phe-MR analysis for TFPI (A) and TMPRSS5 (B).

A.

B.

In general, results can be perceived as the effects of per SD higher circulating protein level on each phenotype. If the effect direction of the target protein on the phenotype is consistent with that on stroke outcomes, it represents “beneficial” additional indications through intervention of circulating protein level. Conversely, opposing effect directions of the target protein on the phenotype and stroke represents “deleterious” side-effects. For example, a higher level of TFPI is associated with lower

risk of ischemic stroke and so phenotypes with $OR < 1$ represents “beneficial effects”, $OR > 1$ represents

“deleterious effects” when the hypothetical intervention increases TFPI levels. Only significant

associations that passed Bonferroni correction ($P \leq 0.05/6/784 = 1.06 \times 10^{-5}$) were plotted. See

Supplementary Table 9 for more clinical information of the ICD code phenotypes.

Table 1. Data sources for the Mendelian Randomization analysis for current study.

Phenotype	Source	N (Total or Cases/Controls)	Imputation reference panel	Ancestry
Olink protein levels	INTERVAL study (unpublished data)	4,994	1000 Genomes Phase 3 + UK10K	European
Inflammation Panel (INF1)				
Cardiovascular Panels (CVD2/CVD3)				
Neurology Panel (NEURO)				
Primary Outcomes				
Any stroke	17 studies (Malik et al) ¹⁷	40,585/406,111	1000 Genomes Phase 1	European
Ischemic stroke		34,217/406,111		
Large artery stroke		4,373/406,111		
Cardio-embolic stroke		7,193/406,111		
Small vessel stroke		5,386/406,111		
Secondary Outcomes				
Atrial fibrillation (AF)	6 Studies (Nielsen, et al) ²⁸	60,620/970,216	HRC*	European
Type 2 Diabetes (T2D)	32 Studies (Mahajan, et al) ²⁹	74,124/824,006	HRC	European
Body Mass Index (BMI)	GIANT + UK Biobank (Pulit, et al) ³¹	694,649	HRC	European
Tobacco and alcohol use	29 Studies (Liu, et al) ³²		HRC	European
AgeSmk		341,427		
CigDay		337,334		
SmkCes		547,219		
SmkInit		1,232,091		
DrnkWk		941,280		
Blood pressure (BP)	UK Biobank (Surendran, et al.) ²⁷	445,415	HRC	European
Systolic BP				
Diastolic BP				
Pulse pressure (PP)				
White Matter Hyperintensity (WMH)	UK Biobank + CHARGE + study in stroke patients (Persyn et al., 2020) ³⁰	42,310	HRC	Trans-ethnic, mainly European
On-target side effects evaluation				
784 Phenotypes	UK Biobank (Zhou, et al) ³³	408,961	HRC	European

*HRC: The Haplotype Reference Consortium (HRC); AgeSmk: Age of Initiation of Regular Smoking; CigDay: Cigarettes per day; SmkCes: Smoking Cessation; SmkInit: Smoking Initiation; DrnkWk: Drinks per week.

Table 2. Proteins representing potential causal factors for stroke and subtypes.

Protein	N SNPs	Outcome	OR [95%CI][#]	P value
TFPI	21	Stroke	0.949[0.926, 0.972]	2.01×10^{-5}
	21	Ischemic-stroke	0.934[0.91, 0.959]	4.68×10^{-7}
TMPRSS5	20	Stroke	1.058[1.039, 1.077]	1.17×10^{-9}
	20	Ischemic-stroke	1.059[1.038, 1.08]	1.36×10^{-8}
	20	Cardioembolic-stroke	1.089[1.045, 1.134]	5.33×10^{-5}
CD40	10	Stroke	0.919[0.891, 0.949]	2.05×10^{-7}
	10	Ischemic-stroke	0.913[0.882, 0.946]	3.61×10^{-7}
	10	Large-artery-stroke	0.795[0.723, 0.874]	2.09×10^{-6}
CD6	23	Stroke	1.039[1.021, 1.057]	1.26×10^{-5}
IL6RA	39	Stroke	0.972[0.96, 0.984]	5.43×10^{-6}
	39	Ischemic-stroke	0.969[0.955, 0.982]	7.99×10^{-6}
	39	Small-vessel-stroke	0.939[0.909, 0.97]	1.60×10^{-4}
MMP12	13	Stroke	0.922[0.901, 0.945]	3.42×10^{-11}
	13	Ischemic-stroke	0.918[0.895, 0.942]	9.07×10^{-11}
	12	Large-artery-stroke	0.793[0.73, 0.861]	3.53×10^{-8}

[#]OR [95%CI]=Odds ratio and its 95% confidence interval per 1-SD higher genetically-predicted plasma protein level

Table 3.

a. MR results of risk factors and stroke outcomes.

Risk Factors	Stroke outcome	N SNPs	OR [95%CI] *	P-value
AF	Stroke	130	1.21[1.18, 1.24]	2.23×10^{-39}
	Ischemic-stroke	130	1.22[1.19, 1.26]	1.11×10^{-39}
	Large-artery-stroke	131	1.04[0.97, 1.12]	0.315
	Cardioembolic-stroke	133	2.04[1.92, 2.16]	2.72×10^{-125}
	Small-vessel-stroke	131	0.99[0.92, 1.06]	0.714
BMI	Stroke	792	1.19[1.13, 1.25]	1.73×10^{-10}
	Ischemic-stroke	791	1.17[1.11, 1.24]	3.25×10^{-08}
	Large-artery-stroke	794	1.29[1.12, 1.49]	3.24×10^{-04}
	Cardioembolic-stroke	792	1.15[1.04, 1.28]	7.49×10^{-03}
	Small-vessel-stroke	794	1.11[0.98, 1.25]	0.118
SBP	Stroke	701	1.67[1.57, 1.78]	1.37×10^{-56}
	Ischemic-stroke	704	1.68[1.57, 1.81]	3.49×10^{-48}
	Large-artery-stroke	710	2.58[2.21, 3.01]	3.69×10^{-33}
	Cardioembolic-stroke	705	1.36[1.2, 1.53]	8.31×10^{-07}
	Small-vessel-stroke	708	1.99[1.72, 2.29]	3.66×10^{-21}
DBP	Stroke	661	1.5[1.4, 1.6]	1.04×10^{-32}
	Ischemic-stroke	667	1.5[1.4, 1.62]	1.67×10^{-28}
	Large-artery-stroke	674	1.72[1.46, 2.02]	5.01×10^{-11}
	Cardioembolic-stroke	673	1.26[1.12, 1.43]	2.11×10^{-04}
	Small-vessel-stroke	677	1.8[1.54, 2.1]	6.30×10^{-14}
PP	Stroke	723	1.4[1.31, 1.49]	1.07×10^{-25}
	Ischemic-stroke	723	1.41[1.33, 1.51]	1.82×10^{-25}
	Large-artery-stroke	725	2.23[1.92, 2.59]	3.29×10^{-26}
	Cardioembolic-stroke	726	1.19[1.06, 1.33]	3.21×10^{-03}
	Small-vessel-stroke	725	1.53[1.34, 1.75]	4.17×10^{-10}
T2D	Stroke	340	1.09[1.07, 1.12]	2.23×10^{-13}
	Ischemic-stroke	341	1.1[1.08, 1.13]	3.96×10^{-15}
	Large-artery-stroke	341	1.24[1.16, 1.32]	1.76×10^{-11}
	Cardioembolic-stroke	337	1.05[1, 1.1]	0.0352
	Small-vessel-stroke	342	1.17[1.1, 1.24]	1.05×10^{-07}
WMH	Stroke	16	1.21[1.07, 1.36]	2.21×10^{-03}
	Ischemic-stroke	17	1.15[1, 1.31]	0.046
	Large-artery-stroke	18	1.13[0.9, 1.43]	0.295
	Cardioembolic-stroke	18	1.14[0.94, 1.37]	0.183
	Small-vessel-stroke	15	1.49[1.17, 1.9]	1.47×10^{-03}
SmkInit	Stroke	365	1.24[1.16, 1.32]	1.80×10^{-11}
	Ischemic-stroke	364	1.22[1.15, 1.31]	6.34×10^{-10}
	Large-artery-stroke	365	1.66[1.42, 1.93]	8.88×10^{-11}
	Cardioembolic-stroke	365	1.11[0.98, 1.25]	0.116
	Small-vessel-stroke	365	1.46[1.25, 1.71]	1.27×10^{-06}

b. MR results of stroke associated proteins and risk factors.

Protein	N SNPs	Risk Factors	OR/ β [95%CI] [#]	P value
TFPI	19	BMI	-0.013[-0.019, -0.007]	3.56×10^{-5}
	19	WMH	-0.06[-0.08, -0.04]	7.15×10^{-10}
TMPRSS5	21	AF	1.03[1.016, 1.045]	2.15×10^{-5}
IL6RA	46	AF	0.959[0.95, 0.968]	2.55×10^{-18}

[#]OR/ β [95%CI]: Odds ratio/log(odds ratio) and its 95% confidence interval, indicates pe-1-SD increase in protein level and its effect on each outcome, if the outcome is a continuous trait, *e.g.* BMI, BP, we report the effect using β , otherwise, we use OR (for binary outcome). OR=Odds Ratio; CI=Confidence Interval; AF=Atrial Fibrillation; BMI=Body Mass Index; WMH=White Matter Hyperintensity; T2D=Type 2 Diabetes; SBP=Systolic Blood Pressure; DBP=Diastolic Blood Pressure; PP=Pulse Pressure; SmkInit=Smoking Initiation.